Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | YAP1 | P46937 | 1/20 | 0.45 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014825 | 0.73 | SMN1; SMN2 (0.38) | TSHRGAAALDH1A1KMT2ALMNA | |
| SCHEMBL22014833 | 0.73 | RAB9A (0.40) | NPC1RAB9AGAAKMT2ALMNA | |
| SCHEMBL22014827 | 0.73 | KMT2A (0.46) | MDM2ALDH1A1KMT2ALMNA | |
| SCHEMBL22014820 | 0.71 | ACACB (0.40) | YAP1TEAD4PKM | |
| SCHEMBL21510197 | 0.71 | PKM (0.54) | TSHRGAAPKMALDH1A1KMT2A | |
| SCHEMBL22014834 | 0.71 | KMT2A (0.30) | KMT2A | |
| SCHEMBL29657316 | 0.70 | PKM (0.61) | TSHRGAAPKMALDH1A1KMT2A | |
| SCHEMBL31629999 | 0.70 | PKM (0.61) | TSHRGAAPKMALDH1A1KMT2A | |
| SCHEMBL21510190 | 0.70 | ALDH1A1 (0.53) | NPC1RAB9ATSHRPKMALDH1A1 | |
| SCHEMBL19011448 | 0.69 | PKM (0.59) | NPC1RAB9AMDM2TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | NPC1 1690/4885RAB9A 3337/4885MDM2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.